US equities lead 2025 ETF flows: A closer look at global trends
Julie Gunts, AllianceBernstein global head of ETF strategy and partnerships, joins Market Catalysts to discuss where flows are heading next.
To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here.
US equity ETFs have seen $191 billion in inflows this year, representing about 60% of total ETF inflows overall, and international equities have had $81 billion in inflows. That's close to the total for all of 2024. As investors weigh continued trade uncertainty, where will the flows go next? Will we see continued trends? Want to bring in Julie Goltz Alliance Bernstein, global head of ETF strategy and partnerships for this week's ETF report brought to you by Invesco QQQ. Julie, thank you so much for being here.
Thanks for having me.
So, I guess it's not a surprise that international has seen big flows. That's what we've seen been seeing and talking about. We look writ large. Where is some of that concentrated? And do you expect that to continue?
Yeah, I think if you look at, you know, the international flows, it's really driven by performance year to date. So, you know, US equities while a volatile first half of the year ended up, you know, 6% for the S&P 500. If you look at the breakdown of international, European equities, in US dollar terms, returned almost 25%. And so I think, you know, ETF flows are to some extent chasing those returns, but I think you know, also expected future returns. And so if you look at the returns in Europe, um, it's driven by industrials, so a lot of the defense companies as Europe is increasing their defense spending and also, you know, infrastructure. European fiscal spending is expected to continue, and their companies set up to benefit from that. We've also seen financials really lead with, you know, the ECB cutting rate, and you know, that benefiting banks and then utilities. Utilities are immune to tariffs, are immune to FX risk, and so have been performing well. On the flip side in Europe, the underperformers consumer discretionary, which is not surprising. Those are global companies impacted by US consumer and potential tariff risk.
And outside of International, where are you seeing kind of interesting demand trends?
Yeah, I mean, we're really seeing demand for emerging market ETFs as well, especially on the active side. So Alliance Bernstein is an active ETF issuer. There aren't that many true fundamental emerging market ETFs out there. Um, and so we're seeing demand for that asset class as, you know, fundamental investing really matters in emerging markets. Um, and so continue to see growth there as well.
That makes sense. Um, you guys only introduced your ETF business what, three years ago?
Yep.
Yeah, I mean it's just been amazing to watch the growth of the industry. How have you guys sort of managed to grab assets in market share? What do you feel like is your angle?
Sure. Yes, so we we launched our first ETFs in September of 2020 2022. So coming up on our three-year mark and have about $8 billion in AUM, and we're really seeing growth, you know, our ETFs are driven by our research, our investment capabilities. And so, you know, long-term investors, you know, looking for active investment strategies. And we've also seen, you know, areas of the market, our municipal bond brand is really strong, and so we have a suite of tax aware ETFs. We've also have, you know, a suite of buffered ETFs that have surpassed a billion dollars. And so taking, you know, unique solutions or different types of investment outcomes and packaging them in ETFs for our clients.
Whether it comes to you guys or the industry writ large, the, you know, pace of record flows that we just continue to see year after year after year, anything that's going to slow that down or is it just going to keep going?
I think it's going to continue to accelerate. Like, so far year to date, we've seen over $600 billion in ETF flows in in the US. Interestingly, active is almost 40% of that, yet still 10% of the AUM. Um, and you know, investors like the ETF vehicle. There's the transparency, the daily liquidity, the tax efficiency. And so as you know, more money is put to work, either from cash on the sidelines or mutual fund single stock investments, ETFs are a really easy option and efficient options for people to get exposure to the marketplace.
You know, I know you've also been you mentioned in the break you've been traveling internationally. What's the ETF industry and demand like outside of the US?
You know, this year we also have seen, you know, real growth in global ETFs. And so global regulators, I think, are, you know, getting on board with that. This is a vehicle, you know, of the future. This is a more modern option for investors. And, you know, for example, I was just in Taiwan. AB is about to launch the first fixed income active ETF in Taiwan. Active ETFs were just allowed from a regulatory perspective earlier this year. And so different pockets of Asia, we're seeing similar trends, um, and in Europe as well. You know, ETFs continue to grow, both in the passive and the active space.
Interesting, Julie. Thank you so much. Appreciate it.
Thank you.
Related Videos
Hilton's upbeat Q2 earnings: Why this analyst is still Neutral
Hasbro Q2 beat, MARA to raise $850M, Otis issues weak guidance
GE Vernova, Thermo Fisher, Enphase Energy: Trending Tickers
Japanese auto stocks are surging on Trump's tariff deal
Effettua l'accesso per consultare il tuo portafoglio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
The Open Group Launches The Open Group Open Digital Transformation™ Forum
Standards body aims to spur faster, more effective transformation initiatives SAN FRANCISCO, July 28, 2025--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. "The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation," commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. "By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices." Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. "Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge," said Steve Nunn, President and CEO of The Open Group. "Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment." To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. View source version on Contacts Media contact Monika BoudovaHotwire for The Open GroupUKOpengroup@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio